Jill DeSimone

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Boston, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Alex Nemiroff, as Attorney-in-Fact
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Jill DeSimone

Form 4 holding Director

iTeos Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
24,200
Estimated value
Report date
11 Jun 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Oncternal Therapeutics, Inc.

Security class
Stock Options
Shares / value
2,200
Estimated value
Report date
20 Jun 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Kinnate Biopharma Inc.

Security class
Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
03 Apr 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Jill DeSimone

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .